Amrize opened lower at $41.34, compared with its previous close of $41.61. In the last trading session, the stock traded between $40.88 and $41.78. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 2 years ago in Amrize is now worth
$ 79.09
resulting in a loss of
$ 20.91 (20.91%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 13 Analysts
Buy
38.46%
Hold
46.15%
Sell
15.38%
Markets Today
Today's Change
$-0.49 (-1.18%)
Day High
$41.78
Day Low
$40.88
Day Open
$41.34
Prev Close
$41.61
Volume
21,19,857
1W Return
4.25%
1M Return
9.05%
3M Return
-16.86%
6M Return
-27.57%
1Y Return
-22.19%
Fundamentals
Market Cap ($ Mn)
22,490
PE Ratio
20.40
PB Ratio
1.91
PEG Ratio
9.27
ROE
9.69%
ROCE
9.14%
EPS (TTM)
-
Investment Returns
1 Week
4.25%
1 Month
9.05%
3 Months
-16.86%
6 Months
-27.57%
9 Months
-24.08%
Financials
Quarterly
All values in $ Mn
2.8K
Dec 24
2.1K
Mar 25
3.2K
Jun 25
3.7K
Sep 25
2.8K
Dec 25
3.5K
Jun 26
Updates
29Oct
Amrize FY26 Results: Sales guidance cut to $12.2B-$12.4B vs est
Amrize reduced FY26 sales guidance to $12.200B-$12.400B. New range is below the $12.540B analyst estimate. Previous guidance was $12.500B-$12.700B.
Yesterday
29Oct
Amrize completes $1 billion share buyback with six months to spare
Amrize repurchased 22,446,667 shares. Total buyback value was $999,991,289. Repurchased shares equal 3.96% of current share capital. Board plans to cancel shares using capital band authority.
Yesterday
20Oct
Barclays lowers Amrize price target to $40, maintains equal-weight
Barclays analyst Adam Seiden lowered Amrize's price target from $55 to $40. The investment rating remains at Equal-Weight. The price target reduction reflects a 27% decrease in valuation estimates.
10 days ago
1Oct
Barclays initiates Amrize with Equal-Weight rating, $55 price target
Barclays initiated coverage on Amrize with an Equal-Weight rating. Price target set at $55 per share. Coverage assigned by analyst Adam Seiden.
29 days ago
2Sep
B of A Securities downgrades Amrize to underperform, cuts target to $40
B of A Securities downgrades Amrize (NYSE: AMRZ) from Neutral to Underperform. Price target lowered from $50 to $40 by analyst Arnaud Lehmann. Move indicates a more cautious outlook on the stock's valuation.
1mo ago
25Aug
Amrize appoints Samuel J. Poletti as CFO, Dillon Cumming to IR
Samuel J. Poletti appointed CFO effective August 24, succeeding Baris Oran. Poletti previously served as Chief Strategy and M&A Officer since June 2025 listing. Dillon Cumming named vice president of Investor Relations, joining September 8. Amrize reported $11.8 billion revenue in 2025 across US and Canada.
